Cardiac resynchronization therapy: a comprehensive review

Moskovitch, Jeremy; Voskoboinik, Aleksandr

doi:10.23736/s0026-4806.18.05861-5

Cited by 8 publications

(7 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite advances in pharmacologic therapies for treating patients with HFrEF, the prognosis of such patients remains poor; therefore, device-based therapy has become increasingly important in recent years for the treatment of HFrEF [43]. The most widely used device-based therapy for the treatment of HFrEF is cardiac resynchronization therapy, which can lead to improved cardiac performance and prognosis in patients with HFrEF and wide QRS (duration > 150 ms) [44]. Unfortunately, only 30% of HFrEF have a QRS duration > 150 ms [45].…”

Section: Cardiac Contractility Modulationmentioning

confidence: 99%

Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction

Alfieri,

Bruscoli,

Di Vito

et al. 2024

Preprint

View full text Add to dashboard Cite

Heart failure (HF) is a growing issue in developed countries and most patients present with a reduced ejection fraction. This condition significantly impairs quality of life and represents a threat not only for patients, but also for the entire healthcare system due to its high management cost. In the last decade, new medical treatments and devices have been developed to reduce HF hospitalizations and improve prognosis, while reducing the overall mortality rate. Medical therapy does not achieve the same results in all patients and, whenever it fails, technology comes in handy: novel devices for the management of HF have reduced symptoms. They have also improved the treatment of fluid retention and life threatening arrhythmias. The present review article gives to the readers a comprehensive overview of the most recent and important findings that need to be considered in HF with reduced ejection fraction patients. Both novel medical treatments and devices have been presented and discussed.

show abstract

Section: Cardiac Contractility Modulationmentioning

confidence: 99%

Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction

Alfieri,

Bruscoli,

Di Vito

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…As HCM progresses, the myocardium becomes more fibrotic and electrically heterogenous, which, in some patients, leads to electrical dyssynchrony. This affliction severely impacts heart hemodynamics and concurs to HF phenomena and increases mortality [49]. The main target of CRT is represented by electrical dyssynchrony, which is considered to be the first event in what is called "dyssynchronopathies".…”

Section: Electrical Parameters In Stratifying Patients With Hcm For Crtmentioning

confidence: 99%

Cardiac Resynchronization Therapy and Hypertrophic Cardiomyopathy: A Comprehensive Review

et al. 2023

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is an inherited primary myocardial disease characterized by asymmetrical/symmetrical left ventricle (LV) hypertrophy, with or without LV outflow tract (LVOT) dynamic obstruction, and poor prognosis. Cardiac resynchronization therapy (CRT) has emerged as a minimally invasive tool for patients with heart failure (HF) with decreased LV ejection fraction (LVEF) and prolonged QRS duration of over 120 ms with or without left bundle branch block (LBBB). Several HCM patients are at risk of developing LBBB because of disease progression or secondary to septal myomectomy, while others might develop HF with decreased LVEF, alleged end-stage/dilated HCM, especially those with thin myofilament mutations. Several studies have shown that patients with myectomy-induced LBBB might benefit from left bundle branch pacing or CRT to relieve symptoms, improve exercise capacity, and increase LVEF. Otherwise, patients with end-stage/dilated HCM and prolonged QRS interval could gain from CRT in terms of NYHA class improvement, LV systolic performance increase and, to some degree, LV reverse remodeling. Moreover, several electrical and imaging parameters might aid proper selection and stratification of HCM patients to benefit from CRT. Nonetheless, current available data are scarce and further studies are still required to accurately clarify the view. This review reassesses the importance of CRT in patients with HCM based on current research by contrasting and contextualizing data from various published studies.

show abstract

“…CRT is the treatment of choice for HFrEF patients with left ventricular ejection fraction (LVEF) <35% and a wide QRS interval [64]. International guidelines recommend CRT in patients with HF, LVEF <35%, who remain symptomatic (NYHA class II-IV) despite optimal medical therapy, and have a left bundle-branch block (LBBB) with a QRS duration >150 ms [65].…”

Section: Crtmentioning

confidence: 99%

Advanced heart failure: state of the art and future directions

Masarone¹,

Kittleson²,

Petraio³

et al. 2022

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Advanced heart failure is a clinical challenge that requires a pathophysiological-based approach. As the field has been the subject of multiple reviews, the objective of this paper is not to duplicate these publications but rather to offer practical tips for the clinical cardiologist to enable the optimal management of patients with advanced heart failure. Advanced heart failure is defined as a clinical syndrome characterized by severe and persistent symptoms, most commonly with severe ventricular dysfunction, despite optimized medical therapy. This review covers the management of the advanced heart failure patient from pharmacologic therapy with diseasemodifying drugs, to the use of electrical therapy devices, percutaneous valve repair and finally to the role of left ventricular assist devices and heart transplantation. The review also explores future directions in the management of advanced heart failure, including translational perspectives for the treatment of this syndrome.

show abstract

Cardiac resynchronization therapy: a comprehensive review

Cited by 8 publications

References 92 publications

Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction

Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction

Cardiac Resynchronization Therapy and Hypertrophic Cardiomyopathy: A Comprehensive Review

Advanced heart failure: state of the art and future directions

Contact Info

Product

Resources

About